Stocks Health care AGMB
NASDAQ · Health careAgomab Therapeutics NV (AGMB)
We have not processed filings for Agomab Therapeutics NV yet. This page fills in on its own once we have read them.
Key facts about Agomab Therapeutics NV
- Net worth
- Agomab Therapeutics NV has a market value (market cap) of $371.8M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on April 23, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Agomab Therapeutics NV does
Agomab Therapeutics NV is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker AGMB.
Earnings: every quarter and the next report date
Latest SEC filings
What Agomab Therapeutics NV has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 13, 2026
- October 1, 2026
- September 14, 2026
- September 11, 2026
- August 10, 2026
- August 6, 2026
- June 23, 2026
- May 27, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Agomab Therapeutics NV did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $503.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Epstein David RDirector | Bought | 5,000 | $34.1K |
| November 5, 2026 | Epstein David RDirector | Bought | 5,000 | $34.6K |
| November 5, 2026 | Epstein David RDirector | Bought | 5,000 | $34.9K |
| October 21, 2026 | Epstein David RDirector | Bought | 5,000 | $44.3K |
| October 21, 2026 | Epstein David RDirector | Bought | 5,000 | $44.5K |
| October 8, 2026 | Epstein David RDirector | Bought | 5,000 | $44.5K |
| October 6, 2026 | Epstein David RDirector | Bought | 5,000 | $43.5K |
| October 6, 2026 | Kemula Pierre Thadee VictorChief Financial Officer | Bought | 3,000 | $26K |
Who owns AGMB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
3 insiders reported holding 71,823 shares in total, about $542.3K at the last price.
| Holder | Shares |
|---|---|
| Epstein David RDirector | 40,000 |
| Knotnerus Tim JasperChief Executive Officer, Director | 21,823 |
| Kemula Pierre Thadee VictorChief Financial Officer | 10,000 |
Questions about AGMB
What does Agomab Therapeutics NV do?
Agomab Therapeutics NV is a company in the Health care sector, listed on NASDAQ as AGMB. Its shares trade on NASDAQ under the ticker AGMB.
What is Agomab Therapeutics NV's net worth?
Agomab Therapeutics NV has a market value (market cap) of $371.8M at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Agomab Therapeutics NV last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 23, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from November 6, 2026.
Similar companies
Compare AGMB with
Follow AGMB
Get an email when Agomab Therapeutics NV files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Agomab Therapeutics NV tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.